|
|
Volumn 18, Issue 11, 1997, Pages 1736-1748
|
|
'Expected infarct size without thrombolysis', a concept that predicts immediate and long-term benefit from thrombolysis for evolving myocardial infarction
a
|
|
Author keywords
Myocardial infarction; Prognosis; Risk factor; Thrombolytic therapy
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ALTEPLASE;
CREATINE KINASE;
FIBRINOLYTIC AGENT;
HEPARIN;
HYDROXYBUTYRIC ACID;
STREPTOKINASE;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
ELECTROCARDIOGRAM;
FIBRINOLYTIC THERAPY;
HEART INFARCTION;
HEART INFARCTION SIZE;
HEART MUSCLE NECROSIS;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
META ANALYSIS;
MORTALITY;
NECROSIS;
PRIORITY JOURNAL;
PROGNOSIS;
REGRESSION ANALYSIS;
RISK BENEFIT ANALYSIS;
SURVIVAL RATE;
SURVIVAL TIME;
TRANSLUMINAL CORONARY ANGIOPLASTY;
|
|
EID: 0030693289
PISSN: 0195668X
EISSN: None
Source Type: Journal
DOI: 10.1093/oxfordjournals.eurheartj.a015168 Document Type: Article |
|
Times cited : (26)
|
|
References (39)
|
